Pharmaceuticals
We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.
We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising. Our clients include Novartis, Pfizer, Bayer, Merck, GSK, and Johnson & Johnson among many others.
Explore our sectors
Meet our lawyers
News & insights
News: 12 FEBRUARY 2021
Allen & Overy advises Biogroup on two high-yield bond issues and a new senior facilities agreement
PARIS – Biogroup, the leading private medical laboratory services group in France and Belgium, has successfully completed through its two main subsidiaries the issuance of EUR800million in aggregate…
Read more
News: 01 FEBRUARY 2021
Allen & Overy continues to make gains with FTSE clients
In the Adviser Rankings 15th anniversary guide A&O is ranked 3rd for FTSE 100 with 23 clients, up from 17 in 2010, and A&O is one of only two magic circle firms to have grown their total stock market…
Read more
Publications: 11 JANUARY 2021
Will the EU-China Comprehensive Agreement facilitate investment by EU companies in China?
The European Union (EU) and the People’s Republic of China concluded the negotiations on their investment treaty, the EU/China Comprehensive Agreement on Investment (CAI), on 30 December 2020.
Read more
Publications: 15 DECEMBER 2020
Healthcare accent is on smaller deals
Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years.
Read moreDownload our sector brochure
